GenePlanet, a biotech company that earlier this year closed an EUR 10m equity deal in exchange for a qualified minority stake with Zurich-based JF Investments AG, is developing a health engagement platform that will function as a personalised prevention programme. Health Intelligence will integrate biological data (genetic and blood tests) with information from smart devices, wearables and sport tracking services.
By setting personal goals and challenges, the user will be able to monitor their progress in specific areas such as nutrition & diet, training & sports, skincare and mental well-being to facilitate long-term behavioural changes that lead to better overall health. “The ultimate digital engagement platform Health Intelligence offers truly personalised recommendations based on real data and action plans to help, advise and improve an individual’s lifestyle through a personalised prevention programme. Our goal is to offer tools that will help people make the best choices for better health and well-being”, GenePlanet’s CEO & Founder, Marko Bitenc, said.
According to the latest data from the World Health Organization, cardiovascular diseases (CVDs) are the number 1 cause of death globally, representing 31% of all global deaths. The vital piece of information from this data is that most cardiovascular diseases can be prevented by addressing behavioural risk factors. “We believe that our new Health Intelligence platform can positively contribute to addressing this health issue and many others”, said Bitenc.
Its participation at the WEBSummit 2018 represents a great opportunity to open the discussion on how technology and prevention programmes can positively contribute to improving people’s health. “We’re excited to be part of the WEBSummit’s rich environment. I believe that we will interact and forge relationships with like-minded innovators”, commented Marko Bitenc.
GenePlanet is specialised in genetic testing and related advanced molecular techniques and recognised for offering personalised DNA analyses. By being R&D oriented, the company constantly strives for new discoveries that enables it to provide its clients with the latest and best products developed from its in-house research and development. The Swiss funds received earlier this year will be used to develop its Health Intelligence platform and for the company’s expansion plan to Asia. The investment represents an important step for the future growth and expansion of GenePlanet, one of the leading genetics companies present in over 30 countries worldwide.
GenePlanet was established in 2008 in Slovenia by Marko Bitenc, a Silicon Valley Singularity University alumnum, and is co-owned by an investment vehicle controlled by Austrian equity investor Gabriel Dielacher, a former Managing Director of Creditanstalt Investment Bank (CAIB).
Through its successful flagship brand NutriFit – with an overall satisfaction rate of 4,62 (out of 5) – it has in the meantime emerged to become one of the most important players in the field of Nutrigenomics where it has developed a wide-ranged client base across different industries – healthcare, wellness and the insurance sector. With a simple saliva-based test, individuals can discover how their genes affect their nutrition, physical activity and lifestyle. Its recently launched the NutriSkin DNA test which focuses on the consequences of genetic mutations that affect one’s skin characteristics and nutritional needs by revealing genetic risks for skin conditions like cellulite, stretch marks and varicose veins.
Moreover, GenePlanet is also strongly committed to diagnostic genetic testing and research. The company offers a non-invasive prenatal testing based on cell-free foetal DNA for detection of Down syndrome and other chromosomal abnormalities (NIPT); accurate test for more than 600 genetic disorders for future parents (Carrier Screen); a test for 87 genetic disorders & 32 medications (Newborn Screen) and Cancer Screen for hereditary cancer risk assessment.